[三季报]一致Ｂ:2021年第三季度报告（英文版）
原标题:一致Ｂ:2021年第三季度报告（英文版） Stock Code: 000028/200028 Notice No.: 2021-37 Short Form of the Stock: Sinopharm Accord /Accord B China National Accord Medicines Corporation Ltd. The Third Quarterly Report for 2021 The Company and whole members of the BOD guarantee that the information disclosed is true, accurate and complete, and there are no any fictitious records, misleading statements or important omissions. Important content reminder: 1. Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents. 2. Principal of the Company, Person in Charge of Accounting Works and Person in Charge of Accounting Organ (Accounting Officer) hereby confirm that the Financial Report of the Third Quarterly Report is authentic, accurate and complete. 3. Whether the Third Quarterly Report has been audited or not □Yes √No I. Main financial data (i) Main accounting data and financial indexes Whether it has retroactive adjustment or re-statement on previous accounting data or not □Yes √No Current period Increase/decrease in the period compared with the same period of the previous year Year-begin to period-end Increase/decrease from year-begin to period-end compared with the same period of the previous year Operating income (RMB) 17,046,925,131.18 8.51% 50,210,017,018.57 17.09% Net profit attributable to shareholders of the listed company (RMB) 332,710,261.54 -6.05% 1,074,155,274.79 7.68% Net profit attributable to shareholders of the 323,929,049.31 -8.58% 1,044,883,457.53 6.48% listed company after deducting non-recurring gains and losses (RMB) Net cash flow from operating activities (RMB) —— —— 1,420,066,537.79 -28.40% Basic earnings per share (RMB/Share) 0.78 -6.02% 2.51 7.73% Diluted earnings per share (RMB/Share) 0.78 -6.02% 2.51 7.73% Weighted average ROE 2.29% 0.36 percentage point down 7.51% 0.05 percentage point down At the end of the reporting period At the end of last year Increase/decrease at the period-end compared with the end of the previous year Total assets (RMB) 44,855,599,672.17 39,594,533,471.65 13.29% Net assets attributable to shareholder of listed company (RMB) 14,679,445,950.04 13,948,322,652.33 5.24% (ii) Items and amounts of non-recurring profit (gains)/losses √ Applicable □ Not applicable In RMB Item Amount for the period Amount from year-begin to period-end Note Gains/losses from the disposal of non-current asset (including the write-off that accrued for impairment of assets) 1,412,736.93 610,707.82 Mainly the gains of disposal of the right-of-use assets from store lease surrender. Governmental subsidy reckoned into current gains/losses (not including the subsidy enjoyed in quota or ration according to national standards, which are closely relevant to enterprise’s business) 14,898,997.98 50,262,339.66 Mainly the various special subsidies and tax rebates received in the Period. When an enterprise acquires a subsidiary, associated enterprise and joint venture, the investment cost is less than the income generated by the fair value of the identifiable net assets of the invested entity 578,610.41 Switch back of provision for depreciation of account receivable and contract assets that are individually tested for impairment 10,000.00 98,994.76 Other non-operating income and expenditure except for the aforementioned items -3,156,204.15 4,384,579.81 Mainly the non-operating income arising from write off funds that do not need to be paid, and non-operating expenses arising from public welfare donation expenses, payment of fines and late fees. Other gains/losses satisfy a definition of extraordinary gains/losses 673,726.22 2,391,162.12 Less: impact on income tax 453,104.34 13,415,430.35 Impact on minority shareholders’ equity (post-tax) 4,604,940.41 15,639,146.97 Total 8,781,212.23 29,271,817.26 -- Other gain/loss items that qualified the definition of non-recurring profit (gains)/losses: □ Applicable √ Not applicable The Company does not have other gain/loss items that qualified the definition of non-recurring profit (gains)/losses Explanation on those non-recurring gain/loss listed in the “Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss” defined as recurring gain/loss □ Applicable √ Not applicable The Company does not have the non-recurring gain/loss listed in the “Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss” defined as recurring gain/loss (iii) Particulars about changes in items of main accounting data and financial index and explanations of reasons √ Applicable □Not applicable (1) Accounts receivable: has an increase of 4,572.2236 million yuan from the beginning of the period with a growth rate of 33.13%, mainly because the account receivable increase with the expansion of sales in the period, as well as the delay appropriation from medical insurance and increase in turnover days of account receivable; (2) Receivable financing: has a decrease of 657.8605 million yuan from the beginning of the period with a growth rate of -46.82%, mainly because the discounted bank acceptance increased in the period; (3) Contract assets: has an increase of 6.1211 million yuan from the beginning of the period with a growth rate of 40.33%, mainly because as the sales of equipment increase, the receivable quality margin for equipment business increases accordingly; (4) Construction in progress: has an increase of 30.8528 million yuan from the beginning of the period with a growth rate of 66.16%, mainly due to the increase of investment for ERP system construction; (5)Short-term borrowings: has an increase of 1,668.7105 million yuan from the beginning of the period with a growth rate of 103.51%, mainly due to the increase in invoice financing of account payable; (6) Accounts payable: has an increase of 3,049.7387 million yuan from the beginning of the period with a growth rate of 39.62%, mainly because as the growth of business, the purchasing volume and account payable increased accordingly; (7) Receipts in advance: has an increase of 4.8947 million yuan from the beginning of the period with a growth rate of 39.63%, mainly because the lease payments received in advance increased; (8) Interest payable: has a decrease of 22.1891 million yuan from the beginning of the period with a growth rate of -62.38%, mainly because as the decrease of non-recourse factoring financing for account receivable, interest payable decreases accordingly; (9) Dividend payable: has an increase of 24.1576 million yuan from the beginning of the period with a growth rate of 378.09%, mainly because the accrual of dividend payable to minority shareholders increased; (10)Long-term borrowings: as an increase of 29.9966 million yuan from the beginning of the period with a growth rate of 94.81%, mainly due to obtaining the long-term credit loans of dedicated equity acquisition; (11) Finance costs: has a year-on-year increase of 78.9280million yuan with a growth rate of 91.05%, mainly because in 2020, the Company has a large-scale acquisitions, and the corresponding consideration for equity acquisition are paid successively, the interest income from deposit declined on a year-on-year basis; (12) Other incomes: has a year-on-year increase of 23.2876 million yuan with a growth rate of 50.42%, mainly because various special subsidies and tax relief received in the period increased on a year-on-year basis; (13) Impairment losses: has a year-on-year decrease of 6.6624 million yuan with a growth rate of -119.34%, mainly due to the reversal of inventory falling price reserves in the period; (14) Gains on disposal of assets: has a year-on-year decrease of 6.3585 million yuan with a growth rate of -86.83%, mainly because the gains on disposal of right-to-use assets arising from off-lease retail stores declined on a year-on-year basis; (15) Non-operating income: has a year-on-year increase of 6.4051 million yuan with a growth rate of 65.50%, mainly because the account payable that do not need to be paid are written off in the period; (16) Non-operating expenses: has a year-on-year decrease of 10.8463 million yuan with a growth rate of -53.18%, mainly because a large amount of litigation compensation occurred in the same period of the previous year; (17) Other cash receipts relating to operating activities: has a year-on-year decrease of 664.6786 million yuan with a growth rate of -54.65%, mainly because the special reserve funds received in the period declined on a year-on-year basis; (18) Cash payments to and on behalf of employees: has a year-on-year increase of 576.5452 million yuan with a growth rate of 30.13%, mainly because the new enterprise consolidated in second half of 2020 made the cash paid to and for the employees increased in the period, and as the expansion of the Company, new pharmacies and number of employees increased, the labor costs are rising rigidly; (19) Cash receipts from returns of investments: has a year-on-year decrease of 16.0302 million yuan with a growth rate of -84.25%, mainly because the investment project withdrawal payment received from Sinopharm Zhongjin Medical Industry Fund declined on a year-on-year basis; (20) Cash received from returns on investments: has a year-on-year decrease of 135.7757 million yuan with a growth rate of -85.09%, mainly because the dividends received from investment in associated enterprise declined on a year-on-year basis; (21) Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets: has a year-on-year decrease of 4.5941million yuan with a growth rate of -87.10%, mainly because the cash received from disposal of fixed assets decreased on a year-on-year basis; (22) Other cash receipts relating to investing activities: has a year-on-year decrease of 21.9850 million yuan with a growth rate of -99.75%, mainly because in the same period of previous year, subsidiary of the Company - Sinopharm Holding Guoda Drugstore Co., Ltd. (hereinafter referred to as Guoda Drugstore) consolidated the subsidiary - Pudong New Area of Shanghai Pharmaceutical Medicine Ltd under the same control, the balance of cash pool originally collected to its former parent company Sinopharm Group Co., Ltd are received, and there is no such event occurred in the period; (23) Total cash inflows from investing activities: has a year-on-year decrease of 178.3851 million yuan with a growth rate of -86.63%, mainly because the dividends received from investment in associated enterprise declined on a year-on-year basis; (24) Cash payments for investments: has a year-on-year increase of 87.8213 million yuan with a growth rate of 309.12%, mainly because the fees for store exchange paid by subsidiary Guoda Drugstore in the period increased on a year-on-year basis; (25) Net cash payments for acquisition of subsidiaries and other business units: has a year-on-year decrease of 2,283.6644 million yuan with a growth rate of -95.77%, mainly because compared with same period of last year, the account of subsidiary acquisition paid by the subsidiary Guoda Drugstore in the period declined; (26) Cash payments related to other investing activities: has a year-on-year decrease of 5.00 million yuan with a growth rate of -100.00%, mainly due to the payment of long-term deposits in the same period of last year, and there was no such event occurred in the period; (27) Total cash outflows from investing activities: has a year-on-year decrease of 2,147.3163 million yuan with a growth rate of -82.37%, mainly because compared with same period of last year, the account of subsidiary acquisition paid by the subsidiary Guoda Drugstore in the period declined; (28) Net cash flows from investing activities: has a year-on-year increase of 1,968.9313 million yuan with a growth rate of 82.00%, mainly because compared with same period of last year, the account of subsidiary acquisition paid by the subsidiary Guoda Drugstore in the period declined; (29) Cash proceeds from investments by others: has a year-on-year increase of 17.2061 million yuan with a growth rate of 100.00%, mainly because received the investment from minorities in the period, and there was no such event occurred in the same period of the previous year; (30) Other cash receipts relating to financing activities: has a year-on-year decrease of 215.6720 million yuan with a growth rate of -67.47%, mainly due to the decrease in borrowing received from minority shareholders in the period, and the mature money order deposit collected in the period decline on a year-on-year basis; (31) Cash repayments for debts: has a year-on-year increase of 673.5614 million yuan with a growth rate of 214.85%, mainly due to the increase in repayment of loans in the period; (32)Effect of foreign exchange rate changes on cash and cash equivalents: has a year-on-year increase of 0.4410 million yuan with a growth rate of 879.85%, mainly due to the impact of exchange rate movements; (33) Net increase of cash and cash equivalents: has a year-on-year increase of 1,082.7871 million yuan with a growth rate of 59.59%, mainly because compared with same period of last year, the account of subsidiary acquisition paid by the subsidiary Guoda Drugstore in the period declined; (34) Cash and cash equivalents at beginning of the year: has a year-on-year decrease of 3,020.9579 million yuan with a growth rate of -35.85%, mainly because in 2020, the Company have large-scale acquisitions, and corresponding consideration of equity acquisition are paid successively, resulting in a decline in balance of cash and cash equivalents at the beginning of the year. II. Shareholders Information (i) Total number of common shareholders and preference shareholders with voting rights recovered and top ten common shareholders In Share Total common shareholders at the end of report period 45,126 Total preference shareholders with voting rights recovered at end of reporting period (if applicable) 0 Top ten shareholders Shareholder’s name Nature of shareholder Proportion of shares held Amount of shares held Amount of restricted shares held Information of shares pledged, tagged or frozen State of share Amount Sinopharm Group Co., Ltd. State-owned legal person 56.06% 239,999,991 5,505,770 FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND Foreign corporation 2.52% 10,802,495 Hong Kong Securities Clearing Company Ltd Foreign corporation 1.96% 8,384,966 China National Pharmaceutical State-owned legal person 1.24% 5,323,043 Foreign Trade Corp. National Social Security Fund- portfolio 413 Domestic non state-owned corporation 1.06% 4,530,032 BBH BOS S/A FIDELITY FD - CHINA FOCUS FD Foreign corporation 0.78% 3,358,761 CPIC Fund- China Pacific Life Insurance Co., Lt. - participating insurance -CPIC fund PICC Stock Relative Income (guaranteed bonus)single asset management plan Domestic non state-owned corporation 0.70% 2,976,701 Fidelity Investment Management (Hong Kong) Limited - Client’s fund Foreign corporation 0.54% 2,308,237 VANGUARD EMERGING MARKETS STOCK INDEX FUND Foreign corporation 0.40% 1,697,229 ICBC- CPIC Desheng Small Selected Securities Investment Funds Domestic non state-owned corporation 0.38% 1,632,000 Top ten shareholders with unrestricted shares held Shareholder’s name Amount of unrestricted shares held Type of shares Type Amount Sinopharm Group Co., Ltd. 234,494,221 RMB ordinary shares 234,494,221 FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND 10,802,495 Domestic listed foreign shares 10,802,495 Hong Kong Securities Clearing Company Ltd 8,384,966 RMB ordinary shares 8,384,966 China National Pharmaceutical Foreign Trade Corp. 5,323,043 RMB ordinary shares 5,323,043 National Social Security Fund- portfolio 413 4,530,032 RMB ordinary shares 4,530,032 BBH BOS S/A FIDELITY FD - CHINA FOCUS FD 3,358,761 Domestic listed foreign shares 3,358,761 CPIC Fund- China Pacific Life Insurance Co., Lt. - participating 2,976,701 RMB ordinary shares 2,976,701 insurance -CPIC fund PICC Stock Relative Income (guaranteed bonus)single asset management plan Fidelity Investment Management (Hong Kong) Limited - Client’s fund 2,308,237 RMB ordinary shares 2,308,237 VANGUARD EMERGING MARKETS STOCK INDEX FUND 1,697,229 Domestic listed foreign shares 1,697,229 ICBC- CPIC Desheng Small Selected Securities Investment Funds 1,632,000 RMB ordinary shares 1,632,000 Explanation on associated relationship among the aforesaid shareholders Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies. (ii) Total shareholders with preferred stock held and shares held by top ten shareholders with preferred stock held □ Applicable √ Not applicable III. Other significant events □ Applicable √ Not applicable IV. Quarterly financial statements (i) Financial statement 1. Consolidate balance sheet Prepared by China National Accord Medicines Corporation Ltd. In RMB Item September 30, 2021 December 31, 2020 Current assets: Cash and bank balances 5,030,550,238.21 5,998,204,295.87 Settlement provisions Capital lent Trading financial assets Derivative financial assets Notes receivable 486,665,614.67 622,115,477.04 Accounts receivable 18,372,194,576.17 13,799,971,014.22 Receivable financing 747,127,225.28 1,404,987,700.38 Advances to suppliers 577,047,357.55 480,313,574.71 Insurance receivable Reinsurance receivables Contract reserve of reinsurance receivable Other receivables 588,663,715.06 535,228,747.69 Including: Interest receivable Dividend receivable Buying back the sale of financial assets Inventories 7,731,292,407.49 6,285,010,674.46 Contract assets 21,298,841.34 15,177,731.64 Assets held for sale Non-current asset due within one year Other current assets 117,800,222.89 121,082,863.45 Total current assets 33,672,640,198.66 29,262,092,079.46 Non-current assets: Loans and payments on behalf Debt investment Other debt investment Long-term account receivable Long-term equity investments 2,506,592,540.54 2,287,019,627.99 Other equity instruments investment 99,488,340.28 99,488,340.28 Other non-current financial assets 135,974,908.51 120,972,350.24 Investment properties 115,666,257.13 127,444,379.94 Fixed assets 846,208,850.06 854,191,083.27 Construction in progress 77,483,997.80 46,631,190.23 Productive biological asset Oil and gas asset Right-of-use assets 2,602,364,849.90 2,356,952,392.99 Intangible assets 738,312,505.33 734,345,179.40 Expense on Research and Development Goodwill 2,932,001,316.63 2,747,375,281.11 Long-term prepaid expenses 547,554,650.71 457,705,276.09 Deferred tax assets 109,492,207.51 92,118,767.81 Other non-current assets 471,819,049.11 408,197,522.84 Total non-current assets t 11,182,959,473.51 10,332,441,392.19 Total assets 44,855,599,672.17 39,594,533,471.65 Current liabilities: Short-term borrowings 3,280,897,558.10 1,612,187,020.12 Loan from central bank Capital borrowed Trading financial liability Derivative financial liability Notes payable 7,348,840,877.78 7,520,165,274.69 Accounts payable 10,747,189,833.18 7,697,451,142.50 Receipts in advance 17,247,134.79 12,352,466.64 Contract liabilities 326,085,220.43 368,600,357.14 Selling financial asset of repurchase Absorbing deposit and interbank deposit Security trading of agency Security sales of agency Employee benefits payable 277,589,432.45 357,212,047.10 Tax payable 278,421,837.51 316,867,149.16 Other payables 1,499,776,310.73 1,599,166,881.14 Including: Interest payable 13,383,522.61 35,572,620.82 Dividend payable 30,546,882.17 6,389,320.96 Commission charge and commission payable Reinsurance payable Liability held for sale Non-current liabilities due within one year 815,092,369.38 748,732,059.89 Other current liabilities 20,574,820.83 24,787,078.55 Total current liabilities 24,611,715,395.18 20,257,521,476.93 Non-current liabilities: Insurance contract reserve Long-term borrowings 61,633,794.44 31,637,173.89 Bonds payable Including: Preferred stock Perpetual capital securities Lease liabilities 1,414,900,980.86 1,303,054,163.90 Long-term payables 6,938,189.00 6,938,189.00 Long-term employee benefits payable 1,262,000.00 1,319,000.00 Provisions 68,663,166.79 68,808,166.79 Deferred income 88,319,436.13 89,843,583.37 Deferred tax liabilities 192,406,210.58 205,921,408.66 Other non-current liabilities 611,494,372.76 740,862,989.59 Total non-current liabilities 2,445,618,150.56 2,448,384,675.20 Total liabilities 27,057,333,545.74 22,705,906,152.13 Equity Share capital 428,126,983.00 428,126,983.00 Other equity instrument Including: Preferred stock Perpetual capital securities Capital surplus 4,371,864,522.76 4,372,504,053.72 Less: Inventory shares Other comprehensive income 38,592,158.00 38,483,017.72 Reasonable reserve Surplus reserve 214,063,491.50 214,063,491.50 Provision of general risk Retained earnings 9,626,798,794.78 8,895,145,106.39 Total equity attributable to owners of the parent 14,679,445,950.04 13,948,322,652.33 Non-controlling interests 3,118,820,176.39 2,940,304,667.19 Total equity 17,798,266,126.43 16,888,627,319.52 Total liabilities and equity 44,855,599,672.17 39,594,533,471.65 Legal Representative: Lin Zhaoxiong Financial controller: Gu Guolin Head of Accounting Department: Wang Ying 2. Consolidated Profit Statement (from the year-begin to the period-end) In RMB Item Current period Last period I. Total operating income 50,210,017,018.57 42,880,505,125.63 Including: Operating revenue 50,210,017,018.57 42,880,505,125.63 Interest income Insurance gained Commission charge and commission income II. Total operating cost 48,889,105,650.99 41,581,721,662.96 Including: Operating costs 44,355,137,220.69 37,944,504,626.84 Interest expense Commission charge and commission expense Cash surrender value Net amount of expense of compensation Net amount of withdrawal of insurance contract reserve Bonus expense of guarantee slip Reinsurance expense Tax and surcharges 118,668,192.68 110,209,795.96 Selling expenses 3,489,636,134.44 2,749,994,678.55 Administrative expenses 760,050,554.53 690,327,040.05 R&D expense Finance costs 165,613,548.65 86,685,521.56 Including: Interest expenses 221,745,036.68 202,695,852.03 Interest income 58,695,611.60 112,936,201.56 Add: other incomes 69,475,290.52 46,187,696.54 Investment income (Loss is listed with “-”) 232,226,696.90 211,950,494.51 Including: Investment income from associates 237,971,923.43 247,559,119.49 Income from the -11,674,941.64 -40,767,172.72 derecognition of financial assets measured at amortised cost (Loss is listed with “-”) Exchange income (Loss is listed with “-”) Net exposure hedging income (Loss is listed with “-”) Income from change of fair value (Loss is listed with “-”) Credit impairment losses/ (Loss is listed with “-”) -31,552,326.70 -29,083,726.06 Impairment losses (Loss is listed with “-”) 1,079,690.03 -5,582,665.20 Gain on disposal of assets (Loss is listed with “-”) 964,385.82 7,322,907.21 III. Operating profits (Loss is listed with “-”) 1,593,105,104.15 1,529,578,169.67 Add: Non-operating income 16,183,608.97 9,778,532.18 Less: Non-operatingexpenses 9,550,290.33 20,396,541.07 IV. Total profit (Loss is listed with “-”) 1,599,738,422.79 1,518,960,160.78 Less: Income tax expenses 328,358,528.63 297,799,939.72 V. Net profit (Net loss is listed with “-”) 1,271,379,894.16 1,221,160,221.06 (i) Classify by business continuity 1. Profit or loss from continuing operations (net loss listed with ‘-”) 1,271,379,894.16 1,221,160,221.06 2.termination of net profit (net loss listed with ‘-”) (ii) Classify by ownership 1. Owners of the parent 1,074,155,274.79 997,585,746.42 2. Non-controlling interests 197,224,619.37 223,574,474.64 VI. Other comprehensive income, net of tax 109,140.28 143,939.42 Other comprehensive income, net of tax, attributable to owners of the parent 109,140.28 143,939.42 (i) Other comprehensive income items which will not be reclassified subsequently to profit of loss 1.Changes of the defined benefit plans that re-measured 2.Other comprehensive income under equity method that cannot be transfer to gain/loss 3.Change of fair value of investment in other equity instrument 4.Fair value change of enterprise's credit risk 5. Other (ii) Other comprehensive income that will be reclassified to profit or loss 109,140.28 143,939.42 1. Other comprehensive income using the equity method that may be reclassified to profit or loss 109,140.28 143,939.42 2.Change of fair value of other debt investment 3.Amount of financial assets re-classify to other comprehensive income 4.Credit impairment provision for other debt investment 5.Cash flow hedging reserve 6.Translation differences arising on translation of foreign currency financial statements 7.Other Net after-tax of other comprehensive income attributable to minority shareholders VII. Total comprehensive income 1,271,489,034.44 1,221,304,160.48 Total comprehensive income attributable to owners of the parent 1,074,264,415.07 997,729,685.84 Total comprehensive income attributable to non-controlling interests 197,224,619.37 223,574,474.64 VIII. Earnings per share: (i) Basic earnings per share 2.51 2.33 (ii) Diluted earnings per share 2.51 2.33 Enterprise combine under the same control in the Period, the combined party realized net profit of 0.00 Yuan before combination, and realized 0.00 Yuan at last period for combined party Legal Representative: Lin Zhaoxiong Financial controller: Gu Guolin Head of Accounting Department: Wang Ying 3. Consolidated Cash Flow Statement (from the year-begin to the period-end) In RMB Item Current period Last period I. Cash flows from operating activities: Cash received from sales of good or rendering of services 50,434,425,085.34 42,418,077,097.10 Net increase of customer deposit and interbank deposit Net increase of loan from central bank Net increase of capital borrowed from other financial institution Cash received from original insurance contract fee Net cash received from reinsurance business Net increase of insured savings and investment Cash received from interest, commission charge and commission Net increase of capital borrowed Net increase of returned business capital Net cash received by agents in sale and purchase of securities Receipts of taxes and surcharges refunds 9,785,028.42 10,784,614.07 Other cash receipts relating to operating activities 551,569,390.53 1,216,248,037.55 Total cash inflows from operating activities 50,995,779,504.29 43,645,109,748.72 Cash payments for goods and services 44,590,896,502.94 37,533,521,802.87 Net increase of customer loans and advances Net increase of deposits in central bank and interbank Cash paid for original insurance contract compensation Net increase of capital lent Cash paid for interest, commission charge and commission Cash paid for bonus of guarantee slip Cash payments to and on behalf of employees 2,490,251,009.84 1,913,705,773.98 Payments of all types of taxes and surcharges 1,163,054,174.01 1,148,433,266.37 Other cash payments relating to operating activities 1,331,511,279.71 1,066,101,719.26 Total cash outflows from operating activities 49,575,712,966.50 41,661,762,562.48 Net cash flows from operating activities 1,420,066,537.79 1,983,347,186.24 II. Cash flows from investing activities: Cash receipts from returns of investments 2,997,441.73 19,027,649.76 Cash received from returns on investments 23,798,335.31 159,574,046.42 Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets 680,564.38 5,274,705.47 Net cash received from disposal of subsidiaries and other units Other cash receipts relating to investing activities 54,984.60 22,040,000.00 Total cash inflows from investing activities 27,531,326.02 205,916,401.65 Cash payments to acquire fixed assets, intangible assets and other long-term assets 242,406,946.82 188,880,164.05 Cash payments for investments 116,231,775.64 28,410,468.41 Net increase of mortgaged loans Net cash payments for acquisition of subsidiaries and other business units 100,950,637.41 2,384,615,064.76 Cash payments related to other 5,000,000.00 investing activities Total cash outflows from investing activities 459,589,359.87 2,606,905,697.22 Net cash flows from investing activities -432,058,033.85 -2,400,989,295.57 III. Cash flows from financing activities Cash proceeds from investments by others 17,206,123.00 Incl: Cash receipts from capital contributions from non-controlling interests of subsidiaries 17,206,123.00 Cash receipts from borrowings 922,684,894.52 801,520,037.57 Other cash receipts relating to financing activities 103,972,601.77 319,644,627.50 Total cash inflows from financing activities 1,043,863,619.29 1,121,164,665.07 Cash repayments for debts 987,061,372.10 313,500,000.00 Cash payments for distribution of dividends or profit and interest expenses 601,040,337.18 545,931,923.60 Incl: Dividends or profit paid to non-controlling shareholders of subsidiaries 54,850,818.34 62,338,791.80 Other cash payments relating to financing activities 1,178,389,883.78 1,661,056,163.63 Total cash outflows from financing activities 2,766,491,593.06 2,520,488,087.23 Net cash flows from financing activities -1,722,627,973.77 -1,399,323,422.16 IV. Effect of foreign exchange rate changes on cash and cash equivalents 390,912.15 -50,126.70 V. Net increase of cash and cash equivalents -734,228,557.68 -1,817,015,658.19 Add: Cash and cash equivalents at beginning of the year 5,405,113,257.99 8,426,071,170.16 VI. Cash and cash equivalents at end of year 4,670,884,700.31 6,609,055,511.97 (ii) Explanation on financial statement adjustment 1. Financial statement adjustment at the beginning of the first year when implementation of new leasing standards from 2021 □ Applicable √ Not applicable （未完）  |